Holen Sie sich die Stockscreener-App
14.67
2.44%
0.35
Vorhandelsmarkt:
14.96
0.29
+1.98%
Schlusskurs vom Vortag:
$14.32
Offen:
$14.53
24-Stunden-Volumen:
4.02M
Relative Volume:
0.67
Marktkapitalisierung:
$4.56B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-124.55M
KGV:
-33.39
EPS:
-0.4393
Netto-Cashflow:
$-95.58M
1W Leistung:
+9.81%
1M Leistung:
+7.79%
6M Leistung:
+668.06%
1J Leistung:
+884.56%
1-Tages-Spanne:
$13.86
$14.95
1-Wochen-Bereich:
$13.16
$15.46
52-Wochen-Spanne:
$1.01
$16.41
Erasca Inc Stock (ERAS) Company Profile
Firmenname
Erasca Inc
Sektor
Branche
Telefon
(858) 465-6511
Adresse
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
14.67 | 4.56B | 0 | -124.55M | -95.58M | -0.4393 |
VRTX
Vertex Pharmaceuticals Inc
|
448.62 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
741.69 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
677.50 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.05 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
275.69 | 30.60B | 5.36B | 287.73M | 924.18M | 2.5229 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Fortgesetzt | Mizuho | Outperform |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-16 | Eingeleitet | Stifel | Buy |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | Jefferies | Buy |
| 2024-03-11 | Eingeleitet | CapitalOne | Overweight |
| 2024-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-30 | Eingeleitet | Mizuho | Buy |
| 2023-02-24 | Eingeleitet | Goldman | Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Erasca Inc Aktie (ERAS) Neueste Nachrichten
Erasca (ERAS) adds 13%; soars 310% YTD - MSN
Assessing Erasca (ERAS) Valuation After ERAS-0015 Licensing Win And Data Anticipation - Yahoo Finance
Certain Stock Options of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2026. - marketscreener.com
TNGX stock hits record high on inking collaboration deal with ERAS - MSN
How Erasca’s Expanded ERAS-0015 License and Narrower 2025 Loss Will Impact Erasca (ERAS) Investors - simplywall.st
Erasca (ERAS) Adds 13%; Soars 310% YTD - Yahoo Finance
5 Stocks Dominating Today’s Market Action - Insider Monkey
Erasca (NASDAQ:ERAS) Shares Up 10.3% on Better-Than-Expected Earnings - MarketBeat
Guggenheim more than doubles Erasca (ERAS) PT following clinical progress and updated pipeline models - MSN
ERAS Surges as JP Morgan Raises Price Target | ERAS Stock News - GuruFocus
JPMorgan Chase & Co. Increases Erasca (NASDAQ:ERAS) Price Target to $25.00 - MarketBeat
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC), Argenx Se (ARGX) and Erasca (ERAS) - The Globe and Mail
Erasca Inc stock hits 52-week high at $14.63 - Investing.com Nigeria
Erasca, Inc. (NASDAQ:ERAS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Chipmakers Recap: Should I invest in Erasca Inc before earnings2026 Valuation Update & Weekly Sector Rotation Insights - baoquankhu1.vn
Erasca Form 144: Foundation Lists Proposed Common Sales | ERAS SEC FilingForm 144 - Stock Titan
Erasca (NASDAQ:ERAS) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Erasca’s Stock Faces Pressure as CMO Offloads Shares - StocksToTrade
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts - AOL.com
Erasca’s CMO Stock Sale Raises Eyebrows Amid Market Uncertainty - timothysykes.com
FTAI Aviation To Rally More Than 43%? Here Are 10 Top Analyst Forecasts For Friday - Sahm
Assessing Tango Therapeutics (TNGX) Valuation After Vopimetostat Progress And New Erasca Collaboration - simplywall.st
Erasca secures worldwide rights to RAS-targeting drug ERAS-0015 By Investing.com - Investing.com Nigeria
Erasca’s Chief Medical Officer Divests Shares Amid Strategic Uncertainties - StocksToTrade
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), MindWalk Holdings (HYFT) and Erasca (ERAS) - The Globe and Mail
Bank of America Securities Sticks to Its Sell Rating for Erasca (ERAS) - The Globe and Mail
Erasca (NASDAQ:ERAS) Price Target Raised to $18.00 at Piper Sandler - MarketBeat
Erasca stock price target raised to $20 by H.C. Wainwright on trial data - Investing.com Nigeria
Erasca (NASDAQ:ERAS) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
Erasca (NASDAQ:ERAS) Given New $20.00 Price Target at HC Wainwright - MarketBeat
Stifel reiterates Buy rating on Erasca stock, $20 target By Investing.com - Investing.com Canada
Stifel reiterates Buy rating on Erasca stock, $20 target - Investing.com
Decoding Erasca Inc (ERAS): A Strategic SWOT Insight - GuruFocus
Erasca, Inc. 2025 Annual Report: Erasing Cancer with Modality-Agnostic RAS/MAPK Pathway Therapeutics and Innovative Precision Oncology Strategies - Minichart
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results - The Manila Times
Erasca 10-K: Net loss $124.55M; cash and securities $341.8M - TradingView
Erasca, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Erasca (NASDAQ: ERAS) narrows 2025 loss and funds runway into H2 2028 - Stock Titan
Cancer-drug maker Erasca raises $259M, says cash lasts to 2028 - Stock Titan
A Look At Erasca (ERAS) Valuation After Securing Global Rights To ERAS-0015 - simplywall.st
Erasca (ERAS) to Release Earnings on Thursday - MarketBeat
Stifel raises Erasca stock price target to $20 on China expansion - Investing.com India
Stifel raises Erasca stock price target to $20 on China expansion By Investing.com - Investing.com South Africa
Finanzdaten der Erasca Inc-Aktie (ERAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.80%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):